
Theriva Biologics announces 1-for-30 reverse stock split effective Dec 2, 2026 to meet NYSE price requirements
Theriva Biologics, a clinical-stage biotech company, announced a 1-for-30 reverse stock split effective December 2, 2026. This move reduces the number of outstanding shares from about 45.9 million to approximately 1.53 million to meet the New York St...





